Adjuvant chemotherapy for osteogenic sarcoma of the extremity with sequential adriamycin and cisplatin.
Twenty-nine patients with high-grade nonmetastatic osteogenic sarcoma of the extremities were treated with adjuvant chemotherapy following definitive surgery. Chemotherapy consisted of systemic intravenous Adriamycin and cisplatin in a sequential fashion given for six courses. Nineteen out of 29 patients are alive and continuously disease free over a follow-up period ranging from 9+ to 30+ months. The relapse-free survival was 72%, and overall survival for the entire group was 69%. Median survival is not reached yet. Six out of 29 patients relapsed, of which 1 patient is alive for 6+ months after relapse. Three patients died of chemotherapy toxicity. The results were superior to historical controls treated with surgery alone. The need for more aggressive treatment approaches is discussed.
Pathak
A B
AB
Department of Medical Oncology, Tata Memorial Hospital, Bombay, India.
Advani
S H
SH
Iyer
R S
RS
Pai
S K
SK
Gopal
R
R
Nadkarni
K S
KS
Saikia
T K
TK
Kurkure
P A
PA
Nair
C N
CN
Pai
V R
VR
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001132:Arm; D001859:Bone Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007866:Leg; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy*; D016019:Survival Analysis
D004317:Doxorubicin; D002945:Cisplatin